Test Price
2,800 AED✅ Home Collection Available
PRRT2 Gene (Benign Familial Infantile Seizures Type 2) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين PRRT2 للنوبات العائلية الحميدة عند الرضع (النوع الثاني) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary (ملخص تنفيذي)
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM daily).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed neurologist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
نقدم تحليلًا جينيًا دقيقًا لجين PRRT2 بتقنية التسلسل المتقدم، معتمدين على أحدث معايير هيئة الصحة بدبي لعام 2026، لضمان تشخيص موثوق للنوبات العائلية الحميدة لدى الرضع.
Test Overview & Methodology
The PRRT2 Gene NGS Test detects pathogenic variants associated with benign familial infantile seizures type 2 (BFIS2), a self‑limiting autosomal dominant epilepsy syndrome. Using whole‑gene Next‑Generation Sequencing (NGS) with >99% coverage of coding exons ±10 bp splice junctions, this test provides superior variant detection compared to targeted genotyping. يكشف تحليل تسلسل الجين الكامل عن الطفرات المسببة بدقة تشخيصية فائقة، مما يضمن توجيهًا سريريًا دقيقًا.
| Feature | Our Test (PRRT2 NGS) | Closest Alternative (Single‑Gene PCR) |
|---|---|---|
| Precision | 99.9% sensitivity; detects SNVs, indels, CNVs across entire coding region | Limited to known hot‑spot mutations; may miss rare or novel variants |
| Method | NGS (Illumina® platform), validated per ISO 9001:2015 | Allele‑specific PCR; lower analytical performance |
| Speed | Report in 3–4 weeks | 2–3 weeks (but compromised clinical utility) |
Physician Insight & Safety Protocol
“As a pediatric neurologist, I understand the distress families face when an infant presents with seizures. The PRRT2 gene test offers definitive clarity, but every result must be correlated with the child’s clinical picture—a normal test does not rule out other epilepsies, and a positive result empowers targeted management. Please discuss all findings with your treating physician before making any decisions.”
— Dr. PRABHAKAR REDDY, DHA License 61713011, Consultant Neurologist
Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Seizure medications should never be altered based solely on a genetic test result.
Exclusion Criteria & Emergency Red Flags
- This test is not indicated for acute seizure management or status epilepticus—seek immediate emergency care.
- Infants with fever, meningitis, or metabolic crises must be stabilized before sample collection.
- ER Red Flags: Prolonged seizure >5 minutes, breathing difficulty, loss of consciousness, or bluish skin—call 998 immediately.
Patient FAQ & Clinical Guidance
1. What is the PRRT2 gene test, and why is it needed for my infant?
The PRRT2 gene test uses next-generation sequencing to detect mutations that cause benign familial infantile seizures type 2, offering a definitive diagnosis for early‑onset epilepsy. يكشف تحليل جين PRRT2 عن الطفرات المسببة للنوبات العائلية الحميدة عند الرضع، ويوفر تشخيصًا قاطعًا لتوجيه العلاج والمتابعة.
2. What sample is required, and how is the home collection arranged?
We require 2–3 mL of whole blood in an EDTA tube, dried blood spot on an FTA card, or pre‑extracted DNA; a certified phlebotomist will visit your home between 8 AM and 11 PM. يتم أخذ عينة دم بسيطة في المنزل بواسطة ممرض معتمد، وتُرسل إلى المختبر بسلسلة تبريد مضمونة.
3. How long will results take, and will a doctor explain them?
The laboratory issues a comprehensive clinical report within 3–4 weeks, and a DHA‑licensed neurologist will provide a telephonic explanation of your child’s results. تصدر النتائج خلال 3 إلى 4 أسابيع، ويتولى طبيب أعصاب مرخص شرح التقرير وجميع الخيارات العلاجية عبر الهاتف.
Regulatory & Accreditation Compliance
- Licensed under DHA Facility License 9834453; ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
- Adheres to Federal Decree‑Law No. 41 of 2024 (Art. 87), UAE Child Data Safeguard Law 2026, and UAE PDPL.
- Pre‑test genetic counselling and informed consent are mandatory per DHA regulations.
- نلتزم بأعلى معايير الخصوصية والسلامة وفقًا للقوانين الصحية الإماراتية.
codes: LOINC 92238-4 | ICD‑10‑CM: G40.89, Z82.0, Z13.85 | Methodology: NGS (2026 validated)
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians